FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 53 filers reported holding FATE THERAPEUTICS INC in Q1 2017. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2017 | $111,000 | -55.2% | 34,107 | -37.5% | 0.04% | -45.0% |
| Q1 2017 | $248,000 | +588.9% | 54,598 | +160.9% | 0.08% | +1042.9% |
| Q2 2016 | $36,000 | -67.3% | 20,925 | -35.6% | 0.01% | -41.7% |
| Q4 2015 | $110,000 | -83.0% | 32,495 | -73.2% | 0.01% | -80.6% |
| Q3 2015 | $646,000 | +22.1% | 121,151 | +48.1% | 0.06% | +19.2% |
| Q2 2015 | $529,000 | – | 81,797 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $200,277,000 | 17.57% |
| Redmile Group, LLC | 12,957,222 | $767,975,000 | 13.39% |
| Copernicus Capital Management, LLC | 12,000 | $711,000 | 8.60% |
| Grosvenor Holdings, L.L.C. | 1,037,256 | $61,478,000 | 7.53% |
| DAFNA Capital Management LLC | 344,360 | $20,410,000 | 5.42% |
| Casdin Capital, LLC | 3,400,000 | $201,518,000 | 5.02% |
| Ally Bridge Group (NY) LLC | 270,000 | $16,003,000 | 4.70% |
| Darwin Global Management, Ltd. | 353,250 | $20,937,000 | 3.85% |
| Bellevue Group AG | 3,238,036 | $191,918,000 | 1.95% |
| Artal Group S.A. | 1,450,000 | $85,942,000 | 1.92% |